AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 106 min read$RPD

Expected Sales In Q2 CY2026, Stock Soars

Rapid7 (NASDAQ:RPD) reported Q2 CY2026 revenue of $210.9 million, down 1.5% year on year but 1.4% above estimates. Next-quarter revenue guidance is $209 million, about 0.9% below analysts. Non-GAAP EPS was $0.44, 26.3% above consensus. The stock rose 6.1% to $12.34 after results.

Original reporting
financialcontent.com
Published Aug 10, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Expected Sales In Q2 CY2026, Stock Soars — source image
Source · financialcontent.com
Decision brief

The 30-second read

$RPDNeutralMed
01

Why it matters

Traders should focus on the combination of a revenue and EPS beat with slightly disappointing next-quarter revenue guidance, plus evidence of stalled ARR growth and negative CAC payback.

02

Market read

A mixed earnings/guidance setup can drive volatility: upside from EPS/operating income beat, offset by softer revenue guidance and weak ARR/CAC signals.

03

What to watch

Negative CAC payback and billings miss could signal sales efficiency deterioration, which may matter more than the single-quarter EPS beat for forward estimates.

Relevance 8/10Novelty 7/10Timing: after-hours/next-session reaction following Q2 results

Background

Rapid7 is a cybersecurity software and services provider; the article frames its Q2 CY2026 results versus Wall Street expectations and discusses ARR and CAC payback.

Company-level read

Ticker impact

$RPDNeutralMedium confidence
Context

Rapid7 reported Q2 CY2026 revenue of $210.9M, beat estimates, but guided next-quarter revenue to $209M below consensus.

Expected impact

Likely supports a bid on earnings quality (EPS/operating income beat) but caps upside due to next-quarter revenue guidance and lack of ARR growth.

Evidence & confidence

Article cites beat on revenue and non-GAAP EPS, yet next-quarter revenue guidance is slightly below analysts and ARR failed to grow, plus CAC payback turned negative.

Market effects

Sector

Cybersecurity SaaS names may see read-through on demand softness if ARR growth remains elusive and guidance stays cautious.

Regional

No specific regional spillover mentioned beyond US-listed software sentiment.

Global

No explicit global macro or international regulatory catalyst cited.

Counterpoint

What could challenge this read

The revenue decline and flat ARR could be temporary, while the EPS and operating income beat may indicate margin improvement that the market is underpricing.

Key entities

  • company
    Rapid7

    NASDAQ-listed cybersecurity software provider reporting Q2 CY2026 results and next-quarter guidance.

  • person
    Wael Mohamed

    CEO quoted on execution and focus as part of the earnings narrative.

Read at source← All news

Related articles

AUG 11
$RPDMedAI 8/10

Why is Rapid7 stock rallying today?

Rapid7 shares rose about 5.1% pre-open after the company reported Q2 2026 results that beat expectations, with adjusted EPS of $0.44 vs $0.35 and revenue of $210.9M vs $208.2M. Rapid7 raised full-year adjusted EPS guidance to $1.78–$1.83 and Q3 EPS to $0.44–$0.47, and approved a restructuring plan cutting staff ~12%.

investing.com4 min
JUL 21
$OFIXMed

These 7 Small Caps Are On Fire In July: Here's Why - ExxonMobil Holdings (NYSE:XOM), Vertex Pharmaceutica

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

benzinga.com7 min
JUL 21
$RPDMedAI 8/10

Rapid7 (RPD) Stock Trades Down, Here Is Why

Rapid7 (NASDAQ: RPD) shares fell 11.3% in the morning after Morgan Stanley downgraded the stock from Equal Weight to Underweight and kept a $9 price target. The firm cited competitive pressure in vulnerability management from AI-focused rivals and said Rapid7 has lagged in exposure management and real-time remediation. RPD is down 26.5% YTD.

financialcontent.com4 min
MAY 28
$RPDMedAI 8/10

Rapid7 (RPD) Releases Findings of Q1 Threat Landscape Report

Rapid7 (NASDAQ:RPD) released its Q1 2026 Threat Landscape Report on May 21, citing vulnerability exploitation as 38% of incident response cases. The company said AI is speeding attackers’ ability to identify and exploit unpatched systems. Separately, Barclays lowered its price target and kept an Underweight rating after Rapid7’s Q1 results, citing weaker-than-expected Q2 ARR guidance. Rapid7 projects Q2 ARR of about $820M versus $832M in Q1.

finance.yahoo.com5 min